CN114965753A - 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 - Google Patents
一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 Download PDFInfo
- Publication number
- CN114965753A CN114965753A CN202210520169.4A CN202210520169A CN114965753A CN 114965753 A CN114965753 A CN 114965753A CN 202210520169 A CN202210520169 A CN 202210520169A CN 114965753 A CN114965753 A CN 114965753A
- Authority
- CN
- China
- Prior art keywords
- lgals3bp
- reagent
- protein
- gestational diabetes
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004104 gestational diabetes Diseases 0.000 title claims abstract description 33
- 102100040510 Galectin-3-binding protein Human genes 0.000 title claims abstract description 31
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 title claims abstract description 29
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 title claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000035935 pregnancy Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000007374 clinical diagnostic method Methods 0.000 claims description 2
- 210000003917 human chromosome Anatomy 0.000 claims description 2
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 239000012530 fluid Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 239000003550 marker Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108010019783 tear proteins Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种检测LGALS3BP蛋白丰度的试剂在制备妊娠期糖尿病泪液诊断试剂中的应用。本发明为妊娠期糖尿病诊断提供了新的诊断标志物，也为诊断妊娠期糖尿病提供了新的诊断方法，由于通过泪液诊断，使用本发明的方法具有无创、操作简单和快速的优点。
Description
技术领域
本发明涉及医学分子检验诊断领域，具体涉及一种LGALS3BP蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用。
背景技术
妊娠期糖尿病(Gestational diabetes mellitus,GDM)指在妊娠前糖代谢正常，在妊娠期间首次诊断出葡萄糖耐受不良症状的一种疾病。妊娠期糖尿病已对我国国民健康造成巨大危害。一方面，随着生活习惯的改变和生育年龄的不断增加，妊娠期糖尿病的患病率在不断增加。另一方面，妊娠期糖尿病可造成巨大儿、剖宫产、早产、子癫前期等不良妊娠结局，并能增加母儿远期代谢综合征的患病风险。因此，有效控制妊娠期糖尿病对我国的民生具有重大意义。
目前，临床上采用的妊娠期糖尿病标准诊断方法为口服葡萄糖耐量试验(OGTT试验)。具体检测方法5min内口服含75g葡萄糖的水，分别于服糖前、服糖后1.0、2.0小时通过静脉采集血样，检测血样中葡萄糖分别低于5.1mmol/L、10.0mmol/L、8.5mmol/L判断受试者糖耐受是否正常。该方法的缺点是耗时且有创，受试者需等待2.5小时完成检测且需通过静脉被采集4次血样，造成患者时间浪费和极差的体验。因此，无创并省时的妊娠期糖尿病诊断方法亟待开发。
泪液是理想的人体疾病诊断体液来源，泪液具有成份浓度稳定、易采集、采集方法无创等优点。因此，本发明开发了一种以泪液为检测对象的一种检测LGALS3BP蛋白丰度的试剂在制备妊娠期糖尿病泪液诊断试剂中的应用。本发明可用于无创、方便、快速的妊娠期糖尿病诊断。
发明内容
有鉴于此，本发明的目的在于提供一种以泪液为检测对象的一种LGALS3BP蛋白丰度检测试剂在妊娠期糖尿病泪液诊断试剂中的应用。
为达到上述目的，本发明提供如下技术方案：
一种检测LGALS3BP蛋白丰度的试剂在制备妊娠期糖尿病诊断试剂中的应用。
优选的，所述LAGLS3BP蛋白的编码基因为LGALS3BP，Pubmed数据库ID为3959，全称描述为galectin 3binding protein，人染色体位置为Chromosome 17,NC_000017.11(78971255-78979923)。
优选的，所述检测LGALS3BP蛋白丰度的试剂指能够检测液体样本中LGALS3BP蛋白丰度的试剂。
优选的，所述LGALS3BP蛋白丰度检测方法包括质谱或ELISA。
优选的，所述妊娠期糖尿病指在妊娠前糖代谢正常，在妊娠期间首次诊断出葡萄糖耐受不良症状的疾病。
优选的，所述诊断试剂的诊断样本为受试者的泪液样本。
优选的，所述妊娠期糖尿病的诊断标准为妊娠期糖尿病患者的泪液样本中的LGALS3BP 浓度显著低于正常女性泪液样本中的LGALS3BP浓度。
优选的，所述葡萄糖耐受不良症状的标准临床诊断方法为口服葡萄糖耐量(OGTT)试验。
本发明的有益效果在于：本发明公开了一种检测LGALS3BP蛋白丰度的试剂在制备妊娠期糖尿病泪液诊断试剂中的应用。本发明可用于无创、方便、快速的诊断妊娠期糖尿病。
附图说明
为了使本发明的目的、技术方案和有益效果更加清楚，本发明提供如下附图进行说明：
图1为质谱分析妊娠期糖尿病患者泪液LGALS3BP蛋白水平；
图2为LGALS3P泪液蛋白水平鉴定妊娠期糖尿病准确性分析。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明，以使本领域的技术人员可以更好的理解本发明并能予以实施，但所举实施例不作为对本发明的限定。
实施例1、质谱分析妊娠期糖尿病患者泪液LGALS3BP蛋白水平
分别采集取经口服葡萄糖耐量(OGTT)试验诊断为妊娠期糖尿病人和普通女性的泪液，提取泪液总蛋白，通过液相-质谱串联技术检测泪液样本中LGALS3BP的蛋白浓度，结果如图1所示。结果显示，妊娠期糖尿病病人的泪液样本中LGALS3BP的蛋白浓度显著低于普通女性泪液种的LGALS3BP的蛋白浓度(Student’s t test，
)。该结果说明泪液LGALS3BP 蛋白水平可作为妊娠期糖尿病诊断的标志物。
实施例2、LGALS3P泪液蛋白水平鉴定妊娠期糖尿病准确性分析
分别采集取经口服葡萄糖耐量(OGTT)试验诊断为妊娠期糖尿病人和正常女性的泪液，提取泪液总蛋白，通过ELISA技术检测泪液样本中LGALS3BP的蛋白浓度，ELISA试剂盒购于abcam公司，货号为ab132454。绘制ROC曲线，结果如图2所示。结果显示，ROC曲线下的AUC值为0.8496，说明LGAL3BP对妊娠期糖尿病有较好的分辨能力。因此，泪液 LGALS3BP蛋白水平可作为妊娠期糖尿病诊断的标志物。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例，本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换，均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (8)
1.一种检测LGALS3BP蛋白丰度的试剂在制备妊娠期糖尿病诊断试剂中的应用。
2.根据权利要求1所述的应用，其特征在于：所述LAGLS3BP蛋白的编码基因为LGALS3BP，Pubmed数据库ID为3959，全称描述为galectin 3binding protein，人染色体位置为Chromosome 17,NC_000017.11(78971255-78979923)。
3.根据权利要求1所述的应用，其特征在于：所述检测LGALS3BP蛋白丰度的试剂指能够检测液体样本中LGALS3BP蛋白丰度的试剂。
4.根据权利要求1所述的应用，其特征在于：所述LGALS3BP蛋白丰度检测方法包括质谱或ELISA。
5.根据权利要求1所述的应用，其特征在于：所述妊娠期糖尿病指在妊娠前糖代谢正常，在妊娠期间首次诊断出葡萄糖耐受不良症状的疾病。
6.根据权利要求1所述的应用，其特征在于：所述诊断试剂的诊断样本为受试者的泪液样本。
7.根据权利要求1所述的应用，其特征在于：所述妊娠期糖尿病的诊断标准为妊娠期糖尿病患者的泪液样本中的LGALS3BP浓度显著低于正常女性泪液样本中的LGALS3BP浓度。
8.根据权利要求5所述的应用，其特征在于：所述葡萄糖耐受不良症状的标准临床诊断方法为口服葡萄糖耐量(OGTT)试验。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210520169.4A CN114965753A (zh) | 2022-05-13 | 2022-05-13 | 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210520169.4A CN114965753A (zh) | 2022-05-13 | 2022-05-13 | 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114965753A true CN114965753A (zh) | 2022-08-30 |
Family
ID=82984171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210520169.4A Pending CN114965753A (zh) | 2022-05-13 | 2022-05-13 | 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114965753A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100163720A1 (en) * | 2006-03-24 | 2010-07-01 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| US20110143453A1 (en) * | 2006-06-14 | 2011-06-16 | Johns Hopkins University | Albumin-bound protein/peptide complex as a biomarker for disease |
| CN106645757A (zh) * | 2017-03-13 | 2017-05-10 | 新疆医科大学 | 一种诊断早发糖尿病mody的血清蛋白标志物组及其应用 |
| CN107024590A (zh) * | 2017-03-13 | 2017-08-08 | 新疆医科大学 | 一种诊断1型和2型糖尿病的血清蛋白标志物组 |
| CN108732356A (zh) * | 2018-02-09 | 2018-11-02 | 深圳大学 | 一种妊娠期糖尿病的妊娠中期诊断标志物及其检测方法 |
| KR20200098440A (ko) * | 2020-07-13 | 2020-08-20 | 서울대학교산학협력단 | 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커 |
| CN113009162A (zh) * | 2021-02-26 | 2021-06-22 | 南芯芯仪(广州)制造有限公司 | 一种用于妊娠期糖尿病诊断的血清代谢标志物及其应用 |
-
2022
- 2022-05-13 CN CN202210520169.4A patent/CN114965753A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100163720A1 (en) * | 2006-03-24 | 2010-07-01 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| US20110143453A1 (en) * | 2006-06-14 | 2011-06-16 | Johns Hopkins University | Albumin-bound protein/peptide complex as a biomarker for disease |
| CN106645757A (zh) * | 2017-03-13 | 2017-05-10 | 新疆医科大学 | 一种诊断早发糖尿病mody的血清蛋白标志物组及其应用 |
| CN107024590A (zh) * | 2017-03-13 | 2017-08-08 | 新疆医科大学 | 一种诊断1型和2型糖尿病的血清蛋白标志物组 |
| CN108732356A (zh) * | 2018-02-09 | 2018-11-02 | 深圳大学 | 一种妊娠期糖尿病的妊娠中期诊断标志物及其检测方法 |
| KR20200098440A (ko) * | 2020-07-13 | 2020-08-20 | 서울대학교산학협력단 | 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커 |
| CN113009162A (zh) * | 2021-02-26 | 2021-06-22 | 南芯芯仪(广州)制造有限公司 | 一种用于妊娠期糖尿病诊断的血清代谢标志物及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| 孙雪林等: "妊娠期糖尿病患者临床特征及糖化血红蛋白测定分析", 宁夏医学杂志, vol. 39, no. 01, 31 January 2017 (2017-01-31), pages 33 - 35 * |
| 邵勇: "妊娠糖尿病诊断的新认识", 实用妇产科杂志, vol. 19, no. 03, 28 June 2003 (2003-06-28), pages 141 - 142 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hossein-Nezhad et al. | Prevalence of gestational diabetes mellitus and pregnancy outcomes in Iranian women | |
| Guerci et al. | Advantages to using capillary blood ɛ-hydroxybutyrate determination for the detection and treatment of diabetic ketosis | |
| Balaji et al. | Inadequacy of fasting plasma glucose to diagnose gestational diabetes mellitus in Asian Indian women | |
| Shahbazian et al. | HYPERTENSION AND MICROAL BUMINURIA 5 YEARS AFTER PREGNANCIES COMPLICATED BY PRE-ECLAMPSIA | |
| Razooki Hasan et al. | Influence of diabetes disease on concentration of total protein, albumin and globulins in saliva and serum: A comparative study | |
| Seshiah | Fifth national conference of diabetes in pregnancy study Group, India | |
| Harding et al. | Reproducibility of oral glucose tolerance data in normal and mildly diabetic subjects | |
| Gupta et al. | Evaluation of correlation of blood glucose and salivary glucose level in known diabetic patients | |
| Kumar et al. | Salivary and serum glucose levels in diabetes mellitus patients versus control–a randomised control trial | |
| RU2557978C2 (ru) | Способ диагностики гестационного сахарного диабета | |
| CN110988165B (zh) | 一种1,5-脱水葡萄糖醇的唾液无创检测方法及其应用 | |
| CN114965753A (zh) | 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用 | |
| Pemde et al. | C-reactive protein in childhood meningitides | |
| JP7354497B2 (ja) | 非侵襲的なＨｂＡ１ｃ値の推定方法 | |
| Holmes et al. | Diabetic status of patients presenting for dental treatment | |
| Martin et al. | The 75 g oral glucose tolerance in pregnancy | |
| CN117969845A (zh) | 预测受试者患有妊娠期糖尿病的泪液标志物ch3l2的应用 | |
| Shahin et al. | Salivary Glucose level as Noninvasive Diagnostic Tool for Monitoring Glycemic Control of Type 1 Diabetic Children | |
| Jorde et al. | Screening for diabetes using HbA 1c in elderly subjects | |
| Ryu et al. | Should the lower limit of impaired fasting glucose be reduced from 110 mg/dL in Korea? | |
| CN112216384A (zh) | 一种糖尿病肾病风险评估系统 | |
| Fritsche et al. | HbA1c measurement cannot replace an oral glucose tolerance test for the diagnosis of gestational diabetes | |
| MANIKANDAN et al. | Comparative study on venous and capillary blood collection for estimation of glucose | |
| CN116908472A (zh) | 一种预测妊娠糖尿病的生物标志物及其应用 | |
| Rinala et al. | Correlation of glucose concentrations in maternal serum and amniotic fluid in high-risk pregnancies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |